Drug intelligence / Profile preview

CP-464005

Development stage: Unknown
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

CP-464005 is an inhaled insulin drug developed by Pfizer. It is being investigated for the treatment of both Type 1 and Type 2 diabetes mellitus. The drug is administered immediately before each meal to help regulate blood glucose levels.

Other names: Inhaled Insulin

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on CP-464005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-464005.

Explore the full profile